2 Passed away prior to publication on 6 April, 2016.
INTRODUCTION
Seizures have a dramatic effect on the autonomic nervous system, and people with epilepsy have an increased risk of sudden unexpected death, termed "Sudden Unexpected Death in Epilepsy" or SUDEP (Tigaran et al . 2003 , Jansen & Lagae 2010 . Seizures can lead to short-term alteration of cardiac rhythm, intracardiac conduction, apnoea and cardiac ischaemia in people (Alehan et al . 2009 , Velagapudi et al . 2012 . It has been suggested that an increased number of generalised seizures leads to an increased risk of SUDEP (Ryu et al . 2015 , Scorza et al . 2016 . In rats with experimentally induced seizures, plasma cardiac troponin I (cTnI) concentrations are elevated following seizures (Metcalf et al . 2009 , Bealer et al . 2010 . This was hypothesised to be a result of seizure-induced cardiac myofilament damage, and the authors suggested routinely measuring cTnI concentrations following seizure activity (Metcalf et al . 2009 ). It has also been suggested that human epileptic patients at risk of SUDEP should have their serum troponin concentrations measured following a seizure (Dupuis et al . 2012 ) . Known SUDEP risk factors include an increased number and frequency of seizures, as well as an increased number of anti-epileptic medications (Lhatoo et al . 2015 , Ryu et al . 2015 .
Seizure activity may lead to increased sympathetic nervous discharge, secretion of adrenaline and noradrenaline and reduced parasympathetic activity in human patients (Blumhardt et al . 1986 , Tigaran et al . 2003 , Mayer et al . 2004 , Velagapudi et al . 2012 . It has been suggested that the resultant increase in heart rate, blood pressure (BP) and myocardial contractility collectively increases myocardial oxygen demand (Alehan et al . 2009 ). Therefore, it is possible that prolonged seizure activity might impose a perfusion/demand mismatch of sufficient severity to produce subendocardial ischaemia (Tigaran et al . 2003 ) . There is also evidence to suggest that direct neural connections to the heart can produce cardiac necrosis lesions in dogs with neurological disease because catecholamines reaching the heart directly via neural connections may be more toxic than those reaching the heart via the bloodstream (Kolin & Norris 1984 , Samuels 2007 .
In dogs, measurement of cTnI concentration can be used to detect myocardial cell injury caused by a variety of causes, including cardiac disease -such as mitral valve disease, dilated cardiomyopathy, subaortic stenosis and pericardial disease (Oyama & Sisson 2004 , Spratt et al . 2005 ) -and non-cardiac disease -such as pyometra (Hagman et al . 2007 ), snake bites (Pelander et al . 2010 ) , renal failure (Sharkey et al . 2009 ), pancreatitis (Serra et al . 2010 ) , canine babesiosis (Lobetti et al . 2002 ) , ehrlichiosis (Diniz et al . 2008 ) , immune-mediated haemolytic anaemia (Gow et al . 2011 ) , parvoviral enteritis (Kocaturk et al . 2012 ) , leishmaniasis (Silvestrini et al . 2012 ) , dirofilariosis (Carretón et al . 2014 ) and gastric dilation-volvulus (Schober et al . 2002 ) . There is little published information on the association of serum cTnI concentration and naturally-occurring seizures in dogs, other than isolated case reports (Kent et al . 2010 , Snyder et al . 2010 , Navarro-Cubas et al . 2011 , Motta & Dutton 2013 , an oral presentation describing a series of cases (Kim et al . 2012 ) and one previously published study (Dutton et al . 2016 ) . It has been shown that cTnI concentrations in dogs with cardiogenic syncope are significantly increased compared with those in epileptic or vasovagal patients, although overlap in levels between groups decreases the discriminatory power of the test for individual dogs (Dutton et al . 2016 ) . No studies have evaluated cardiac troponin concentrations in a population of dogs with seizures that have no evidence of underlying cardiac or metabolic disease and compared them to a healthy control population of dogs. It is important to have information concerning the response of cTnI concentrations following a seizure to enable the correct interpretation of serum concentrations obtained from patients following a paroxysmal event (such as a seizure or syncopal episode).
The primary aim of the current study was to compare serum cTnI concentrations in dogs following generalised seizures with concentrations obtained from an age-matched control population of healthy dogs. Secondary aims of the study included identifying whether clinical variables, such as age and seizure number, were associated with serum troponin concentrations and comparing troponin concentrations obtained using different cardiac troponin assays.
MATERIALS AND METHODS
The study protocol was approved by the University of Cambridge ethical review committee. Dogs with generalised seizures and healthy controls were prospectively and consecutively recruited at two referral centres between February 2011 and May 2013. The dogs with seizures included newly diagnosed dogs and those already receiving treatment. To be included as a case, a dog must have experienced a generalised seizure within 7 days of presentation and undergone full cardiac investigations, including BP measurement, electrocardiography (ECG) and echocardiography without a cardiac abnormality being discovered. Dogs had to be free from other disease likely to lead to altered serum troponin concentration, such as pancreatitis, immunemediated haemolytic anaemia and renal insufficiency, based on history, clinical examination, urine specific gravity measurement, complete blood count, serum biochemistry and electrolytes. Dogs were excluded if they showed evidence of renal insufficiency [based on elevated serum creatinine concentrations (>150 µ mol/L) and low urine-specific gravity (<1·030)], metabolic disorders that could have caused the seizures (hypocalcaemia or hypoglycaemia) or had a history of recent trauma or intoxication.
Healthy control animals consisted of staff pets undergoing blood sampling for screening before vaccination, blood donation or elective surgery. They had to have no abnormalities detected on full clinical, including neurological, examination. They had no history of seizures and were free of any disease likely to lead to elevated serum cTnI concentrations. They also had to be free of cardiac disease based on clinical examination, BP, ECG and echocardiography.
Signalment (breed, age, gender, neutered status, bodyweight), history (including time since seizure, in hours, until blood sampling) and current medication (yes/no) were recorded. For the patients with seizures, the number of seizures during the 7 days before presentation and seizure length in minutes (if more than one seizure had occurred, then the average seizure length) were noted. Full neurological examination was performed.
Fasting blood samples for the measurement of creatinine concentration ( µ mol/L) were collected from all dogs and analysed within 24 hours. Blood was collected into 1 mL serum gel tubes and separated by centrifugation 30 minutes after being left to stand at room temperature. Serum was then chilled at 4°C for up to 12 hours before transportation at ambient temperature to a commercial laboratory [Carmichael Torrance Diagnostic Services (CTDS) Ltd, W Yorks] for analysis. Free-catch urine samples were obtained the same day as blood sampling, and urine-specific gravity was measured. Laboratories were blinded to patient history.
Samples analysed using the first-generation cTnI assay (FGcTnI) were handled as described for serum creatinine and were analysed using a previously described chemiluminescent immunoassay system (Troponin I Immulite ® 1000 Siemens Medical Solutions; O'Brien et al . 2006 ) . The cTnI was detected using an enzyme-conjugated polyclonal anti-troponin I antibody following protein binding onto beads coated with murine anti-troponin I antibody, using the Immulite ® Analyser. Both antibodies recognise epitopes between amino acids 33 and 110 of cTnI. Sample handling for the high-sensitivity cTnI assay (hs-cTnI) involved collecting blood into 1 mL plain tubes. Plain tube samples were separated by centrifugation immediately after clotting. The serum was then stored for up to 12 hours at −18°C before transportation in frozen cool packs to a commercial laboratory (IDEXX Laboratories, Accredited for analytical testing BS ISO/IEC 17025:2005) . The high-sensitivity assay (AccuTnI ® assay) is a two-site sandwich immunoassay (Access Systems AccuTnI ® Assay, Beckman Coulter Inc), which detects free and complex troponin. The assay uses two mouse-derived monoclonal antibodies directed against 24 to 40 and 41 to 49 amino acid sequences of cTnI. This assay has been reported (Adin et al . 2006 , Hezzell et al . 2012 ) and validated (Oyama & Solter 2004 ) previously for canine samples. The laboratory reference range was cTnI <0·15 ng/mL for the FG-cTnI assay and ≤0·07 ng/mL for the hs-cTnI assay. The assay lower limits of detection (LOD) were 0·02 ng/mL (FG-cTnI) and 0·01 ng/mL (hs-cTnI). Samples for measuring serum cTnI concentrations using both methods were taken from patients at presentation. For patients with seizures, cardiac investigations occurred before general anaesthesia (GA), except for any difficultto-control status epilepticus (SE) patients, where cardiac investigations were delayed until 24 hours following GA. Systolic BP (mmHg) was measured using a Doppler device according to an established protocol (Brown et al . 2007 ). Five readings were taken, and the mean was calculated. ECG used a routine six-lead ECG machine (Esaote P80 Power or Seca CT8000P), with a period of acclimatisation beforehand. Six limb leads were recorded simultaneously for a minimum of 20 consecutive RR intervals at a paper speed of 50 mm/second, with a gain of 10 mm/mV.
Patients underwent full 2D echocardiographic examination without sedation, according to published recommendations (Thomas et al . 1993 ), using phased array probes (1·5 to 11 MHz) with harmonic imaging (Esaote Piemedical MyLab 40 Vet or Vivid S6 echocardiography machines). An ECG was recorded simultaneously. Full M-mode, colour and spectral Doppler studies were recorded and analysed. All cardiac investigations were performed by the same resident in cardiology, working under the supervision of a Royal College of Veterinary Surgeons (RCVS) specialist in veterinary cardiology.
Dogs with suspected seizures underwent appropriate imaging. Magnetic resonance imaging (MRI) scans (0·25 T; Vet-MR Grande, Esaote) with gadolinium contrast were obtained in three planes of orientation (dorsal, sagittal and transverse) under GA. Pre-and postcontrast T1-weighted and T2-weighted images were acquired. In some cases, additional sequences (pre-and postcontrast FLAIR, gradient echo T2* and STIR) were carried out to better define the underlying brain disease. Additional tests, such as Toxoplasma and Neospora serology, were performed by the attending clinician depending on the individual case. All neurological examinations were performed by European College of Veterinary Neurology board-certified neurologists or their residents. Definitive diagnosis of the cause of seizures was made by evaluating all contributing evidence, with idiopathic epilepsy being a diagnosis of exclusion (Berendt et al . 2015 ) . Dogs with idiopathic epilepsy were younger than 6 years at seizure onset, had recurrent seizures and were normal on interictal neurological and laboratory examination. They had no evidence of neurological disease, other than seizures, during their lives up until presentation. Dogs were grouped into healthy controls (group C) or those with generalised seizures but no evidence of cardiac disease (group S). Data were analysed using commercially available software (Prism 7 for Windows version 7·02, Graphpad Software Inc.; IBM SPSS Statistics version 22·0.0·1). Continuous variables were checked to see whether they came from a normal distribution using a Shapiro-Wilk test. In descriptive statistics, continuous variables from a normal distribution are reported as mean (±sd) and those not from a normal distribution as median (range). The cTnI concentrations below the LOD of the assays used were ascribed the value of the LOD: 0·01 ng/mL for the hs-cTnI assay and 0·02 ng/mL for the FG-cTnI assay.
Simple linear regression was performed with the cTnI concentration as the dependent variable. The following predictor variables were initially assessed individually for an association with the dependent variable: presence of seizures (y/n), seizure number (during seven days before presentation), seizure length (minutes), serum creatinine concentration ( µ mol/L), age (years), sex (male or female), neutered status (neutered/entire), bodyweight (kg), time since seizure (hours) and whether anticonvulsant medication was being administered at presentation and systolic BP (mmHg). For dogs recorded as having greater than 10 seizures within 7 days of presentation, the seizure number was arbitrarily allocated to 11. This allowed dogs with a frequent, but unknown, precise number of seizures to be entered into the analysis. Those predictor variables demonstrating an association with the dependent variable with P<0·2 in the univariable analysis were taken forward to the multi-variable analysis. Multi-variable linear regression analysis was performed with log 10 values of cTnI concentrations obtained from all dogs (those with seizures and controls) as the dependent variable. Two sets of analyses were performed, one using concentrations obtained with the FG-cTnI assay and one using those from the hs-cTnI assay. The analysis was performed in a backward stepwise manner, with the variable showing the highest P value excluded from the model at each step until all remaining variables had a P value less than 0·05. Final models were assessed for adequacy of fit using the adjusted R-square. The residuals of the final models were checked to confirm that they adequately met the model assumptions. Model assumptions were normality, linear relationship with an additive effect of the predictors, homoscedasticity and independence of the errors. The first assumption was checked using visual inspection of a histogram and normality tests of the residuals; to ensure the other assumptions were met, the plots of the residuals were examined against fitted values and against their order in the data set.
Concentrations of cTnI obtained using the two different assays were correlated using Spearman's rank correlation and compared using the Wilcoxon signed-rank test. The latter analysis was performed using all values obtained from all dogs, including those with values ascribed at the LOD of the assay. The comparison was then repeated including only those animals in which concentrations measured using both assays were above 0·02 ng/mL (i.e. above the LOD of both assays). A Bland-Altman plot of the difference in concentration obtained between the two assays plotted against the average of the two assays was created.
For all analyses, P values of <0·05 were accepted as statistically significant. 
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RESULTS
Sixty dogs were enrolled, consisting of 30 dogs with seizures (group S) and 30 control dogs (group C). One dog with seizures was excluded from all statistical analyses except the comparison of cTnI concentrations obtained using the different assays because it had no BP, ECG and echocardiographic examination and therefore did not fully meet the entry criteria. Signalment and other baseline characteristics are summarised in Table 1 . The distribution of breeds was different between groups (Table 1 ) . Group S comprised 26 dogs with primary (idiopathic) epilepsy, two with brain tumours (suspected meningioma and suspected glioma) and one with necrotising meningoencephalitis. Three dogs had SE during the 24 hours before presentation, one of which required GA for seizure control. The median number of seizures in group S was two (range 1 to 11). The median seizure length was 3 minutes (Table 1 ) .
In group S, 17 dogs were taking anticonvulsant drugs at presentation, including phenobarbitone (Epiphen; Vetoquinol), levetiracetam (Keppra; UCB), potassium bromide (Epilease; Vet Plus Ltd), gabapentin (Neurontin; Pfizer) and diazepam (Diazepam Rectubes; Wockhardt). Other medications included oral antibiotics (n=1) and injectable dexamethasone (n=1) (Dexadreson; Intervet UK Ltd). No control dogs received medication. All but one of the dogs had normal ECGs and echocardiographic examinations. An echocardiographic abnormality was detected in one case in group S (mild left ventricular dilation), but this was attributed to sinus bradycardia (heart rate of 60 bpm). Repeat echocardiography performed three weeks later, when the patient was in normal sinus rhythm (120 bpm), was unremarkable.
Serum concentrations of cTnI [median (range)] were higher in dogs after a seizure compared to controls when measured by both assays (FG-cTnI assay, dogs with seizures median 0·07 [0·02 to 3·05] versus control dogs median 0·05 [0·02 to 0·13] ng/mL; P=0·014 (Fig 1 ) and hs-cTnI assay, dogs with seizures median 0·03 [0·01 to 1·92] versus control dogs 0·02 [0·01 to 0·05] ng/mL; P<0·001). Seven dogs (one with seizures and six control dogs) had troponin concentrations at or below the LOD of the FG assay. Seventeen dogs (three with seizures and 14 control dogs) had troponin concentrations at or below the LOD of the hs assay. As the distribution of troponin concentrations was skewed, logarithmic transformation was required for linear regression analyses. The results of the simple linear regression with a single predictor are reported ( Table 2 ). The final models of the multi-variable linear regression analyses indicated that an increasing number of seizures (P<0·001) and increasing age (P<0·001) were significantly associated with higher concentrations of cTnI measured using both the FG-cTnI and hs-cTnI assays, and both predictors had positive regression coefficients (Table 3 ). The adjusted R-square value was greater for the model in which concentrations obtained with FG-cTnI assay were used as the dependent variable (adjusted R-square 0·48 with FG-cTnI assay and 0·44 with hs-cTnI assay). The residuals of the multiple regression analysis were normally distributed for the final model using FG-cTnI as the dependent variable but not for the final model using hs-cTnI. For these reasons, the FG-cTnI model is the one for which the associations are reported.
As would be expected, troponin concentrations measured using the FG-cTnI assay correlated well with those of the hscTnI assay, r=0·82 (P<0·001). However, the values obtained with the FG-cTnI assay were significantly higher than those obtained using the hs-cTnI assay. This was the case when data from all 60 dogs was analysed and when only those 23 dogs for which values were greater than 0·02 ng/mL when measured by both assays were compared (P<0·001 for both comparisons). The Bland-Altman plot suggested that values obtained with the FG assay were consistently higher than those obtained with the hs assay (Fig 2 ) .
DISCUSSION
Our data show that dogs with generalised seizures have higher circulating serum cTnI concentrations compared with healthy control dogs. The results also indicate that the degree of troponin elevation is independently associated with the number of seizures experienced and the age of the dog. These results are similar to those from a study of human patients which demonstrated that cTnI concentration increased with increased seizure number (Hajsadeghi et al . 2009 ). Myocardial injury in the setting of seizure activity could be expected given the apnoea, tachycardia, increased myocardial oxygen consumption and excess catecholamine release associated with seizures, which has been observed in experimental rat models (Metcalf et al . 2009 ). It is important to know that dogs that have recently experienced seizures may have elevated cTnI concentrations because seizures, which can be challenging to differentiate from syncope, are another cause of elevated cTnI in dogs without primary cardiac disease. A previous study suggested that serum cTnI is significantly higher in dogs following syncope compared with epilepsy in the absence of cardiac disease, although significant overlap compromised the diagnostic utility of cTnI for the differentiation of these causes of episodic collapse in individual animals (Dutton et al . 2016 ). The present study demonstrated similar findings in the dogs following seizures and, additionally, that cTnI concentrations increase with increasing number of seizures and age. These findings suggest that a diagnosis of cardiac syncope should not be based on cTnI alone and that further research is warranted in finding diagnostic tests that could help differentiate cardiac syncope from epileptic seizures.
Elevated cTnI concentrations may also be due to cardiac necrosis caused by catecholamines released directly into the myocardium via neural connections, as suggested by experimental models and studies on human patients with intracranial lesions (Burch et al . 1969 , Kolin & Norris 1984 , Shivalkar et al . 1993 . It is also possible that myocardial fibrosis, such as that shown to occur in human SUDEP patients, may occur particularly following repetitive autonomic stimulation, i.e. with an increased number of seizures (Earnest et al . 1992 , Natelson et al . 1998 . In humans, an increased number of seizures has been shown to be a risk factor for SUDEP (Lhatoo et al . 2015 ) . It is therefore possible that an increasing number of seizures might be causative for increased myocardial injury, although further studies are necessary to investigate this possibility. In addition to relevance to SUDEP, this is an argument for improved seizure control.
In the population we describe, circulating cTnI concentrations increased with age, consistent with previous canine studies (Oyama & Sisson 2004 , Hezzell et al . 2012 . One possible cause is that in the aged heart, even in the absence of demonstrable cardiovascular disease, there is gradual loss of cardiac myocytes. Tropinin in the circulation may therefore represent myocyte death, or turnover, which may be a normal consequence of ageing (Oyama & Sisson 2004 ) . Another possibility is decreasing renal clearance of troponin with increasing age. However, in this study, patients with chronic kidney disease (creatinine concentrations>150 µ mol/L and USG<1·030) were excluded, and no association between cTnI concentrations and creatinine was observed. Further studies are required to investigate why troponin concentrations are positively associated with age in the absence of renal dysfunction. Multi-variable analysis adjusts the analysis for the effect of age, and therefore, the effect of seizure number is independent of the effect of age.
We measured serum troponin I concentrations using two different assays, thereby generating similar results in the multi-variable analyses. The FG-cTnI assay was able to detect cTnI in the serum of a greater proportion of the dogs, with fewer results below the LOD of the assay, despite the assay having a higher LOD. The LOD reported for the FG-cTnI assay used in the current study was 0·02 ng/mL, which is lower than the LOD previously reported for this assay (Spratt et al . 2005 ) . This was the LOD reported by the commercial laboratory that ran the analyses and was chosen on the basis of good dilutional linearity of the assay, down to concentrations below 0·02 ng/mL, demonstrated by the laboratory's own validation studies (personal communication).
The FG-cTnI assay demonstrated less clustering of values than those obtained with the hs-cTnI assay. As a result perhaps, the data obtained using the FG-cTnI assay resulted in a slightly higher R-squared value for the final model using this as the dependent variable. Values obtained with the FG-cTnI assay were significantly higher than the hs-cTnI values for the same patients. Explanations for higher cTnI values include different target amino acids for each analyser and differences in antibody specificity for free and complex troponin (James et al . 2006 ) . In human patients, various troponin assays have been compared, and some were shown to be superior to others (James et al . 2006 ) . Our study confirms that, despite close correlation, the two troponin assays cannot be used interchangeably, which has also been shown in a previous veterinary study (Adin et al . 2006 ) .
In this study, a control population was included, and patient numbers were higher than in a previously reported study on serum cTnI with seizures (Kim et al . 2012 ) . A more homogenous population of dogs was included here, the majority suffering from primary (idiopathic) epilepsy, and other included dogs were also free of significant metabolic disease. This homogeneity allows the effect of variables such as seizure number and length to be analysed without underlying disease processes confounding the results. The disadvantage is that the effect of different types of underlying disease upon troponin concentration cannot be compared. As troponin concentrations can change with non-cardiac disease, eliminating chronic kidney disease, immune-mediated haemolytic anaemia, sepsis, pyometra, respiratory disease and pancreatitis on history, clinical examination and blood tests was an important component of this study.
This study has a number of limitations. None of the patients had myocardial biopsies, coronary angiography or post-mortem examinations to confirm myocardial cellular damage and rule out other possible causes of cTnI release. The cases presented here represent a referral population, which may differ from the population of dogs seen in primary care practice. The breed distribution of the control and seizure groups was different, and the effect of breed on cTnI concentrations was not examined. This is unlikely to have had an effect on the overall findings but is a potential confounder. The results of the study only apply to the two troponin analysers used, and the results cannot be used interchangeably. The effect of GA on troponin concentration was not assessed in this study, although only one patient required GA for seizure control and therefore had cTnI sampling delayed until 24 hours following GA. This same patient had the highest serum cTnI concentration in group S and had sinus bradycardia at 60 bpm. It is unclear whether the changes detected were a result of anti-epileptic medications, GA or a direct result of the high number of seizures. It is possible that the GA affected serum cTnI concentrations, resulting in elevated levels. However, two other epileptic patients also had elevated cTnI concentrations (according to the laboratory reference range) and yet did not require GA for seizure control. Interestingly, both patients suffered a high (>10) number of seizures before blood sampling. Excluding the data of the one patient that underwent anaesthesia from the multi-variable analysis did not substantially alter the results obtained. Further studies involving larger numbers of patients with seizures, pre-and post-GA, would be required to further investigate this association with serum cTnI concentrations. Finally, it is possible that in three dogs (two with brain tumours and one with necrotising meningoencephalitis) suffering seizures, the underlying disease process may have had an effect on the serum troponin concentrations rather than the seizures themselves. Larger studies would be required to study the effects of individual disease processes on troponin concentrations as, so far, only individual case reports are available (Snyder et al . 2010 , Navarro-Cubas et al . 2011 ).
In conclusion, our results suggest that serum troponin concentrations are elevated in dogs with seizures when compared to healthy controls. The elevation is independently associated with number of seizures when adjusted for the influence of age. The identification of elevated cTnI concentrations is important as it suggests that myocardial injury might occur secondary to seizure activity, which could have clinical implications for epileptic patients. In addition, the positive relationship between seizure number and serum cTnI concentration is likely to further reduce the diagnostic utility of serum cTnI for differentiation of syncope and seizure activity.
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